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Background: When opioid-agonist treatments were approved in France in 1995, opiate use disorders began to be
managed and treated by general practitioners (GPs), who have since then been encouraged to treat substance use
disorders (SUDs) for heroin and other illegal substances. The objective of this study was to describe rates of: 1) SUDs
in general practices in France; 2) characteristics of GPs treating SUDs; and 3) clinical practices surrounding SUDs. To
place these data in the context of SUD treatment, we also gathered information from practicing SUD specialists.
Methods: Between December 2011 and January 2012, a nationally representative sample of GPs and SUD
specialists were interviewed by phone, using a 12-item questionnaire that covered number of SUD patients, types
of SUDs, and treatments. Data collected were confidential, and analysis was blinded with regard to physician
identity.
Results: Forty-four percent of GPs and 68 % of specialists were included in the analysis. The mean number of
patients estimated to have been seen at least once in the previous year was 3036 for GPs and 920 for specialists.
Ninety-six percent of GPs reported having patients with SUDs. Tobacco, alcohol, and psychoactive drugs were the
SUDs most frequently encountered by GPs, whereas tobacco, alcohol, heroin, and cannabis were most frequently
encountered by specialists. Forty-three percent of GPs saw at least one patient with a heroin use disorder (HUD),
and 82 % of GPs treating patients with HUDs had prescribed an opioid-agonist treatment during the previous
12 months.
Conclusions: The results of this study suggest that a large number of GPs now treat patients with opiate use
disorders and that doctors appear to be convinced of the benefits of opioid-agonist therapy and have overcome
their initial concerns. This represents a significant change in practice patterns since the introduction of
opioid-agonist treatments in France.
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Opioid-agonist managementBackground
In 1995, opioid-agonist therapy (OAT) was approved in
France as maintenance therapy for major opiate sub-
stance use disorders (SUDs) [1], with the stipulation that
initiation of methadone treatment take place in special-
ized SUD centers and that general practitioners (GPs)
only be allowed to renew methadone prescriptions and* Correspondence: pierre.polomeni@rmb.aphp.fr
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creativecommons.org/publicdomain/zero/1.0/to prescribe buprenorphine-based treatments alone or in
combination with naloxone. At the end of the 1990s, the
treatment and management of SUDs was reorganized with
the creation of specialized centers (Centres d’Accompag-
nement et de Prévention en Addictologie [CSAPA]),
which had broader mission statements, centers for the re-
duction of risk (Centres d’Accueil et d’Accompagnement à
la Réduction de risques pour Usagers de Drogue), and an
SUD subspecialty in medical curriculums [2]. As a result
of these measures, GPs, who were encouraged to be more
involved in the treatment of opiate use disorders, haves article distributed under the terms of the Creative Commons Attribution
by/2.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Data published in 2012 showed that 260,000 patients were
being treated with agonist strategies, most of which were
being prescribed by GPs in private practice [3]. In
addition, GPs have been able to take a broader approach
and integrate the management of opiate use disorders
with the management of other SUDs for alcohol, tobacco,
and other prescription medications.
Our study describes current treatment practices of
GPs in France. Data describing the prevalence of SUDs
in general practices, the role of GPs in the management
of opiate use disorders, and their prescription choices
were gathered through a phone survey. To place these
data in the context of SUD treatment in France, we also
gathered information from practicing SUD specialists.
Methods
This pilot study, conducted by the healthcare department
of the French Institute of Public Opinion (Institut français
d’opinion publique), was a quantitative survey of GPs and
specialists affiliated with CSAPA centers. Health profes-
sionals were interviewed by phone using contact informa-
tion obtained from a national roster. All physicians
provided explicit informed consent, and all data were
treated confidentially. Data collection and analysis were
performed according to the requirements put forth by the
National Commission for Data Protection and Liberties.
The survey was conducted from December 12, 2011, to
January 6, 2012.
Questionnaire
The questionnaire included 12 questions designed to as-
sess current practices in the treatment and management
of opiate use disorders. The survey started with screen-
ing and demographic questions designed to collect infor-
mation about provider specialty (GP, GP specialized in
SUDs, specialist [psychiatrist or other]); main place of
practice (private practice, specialized SUD center, other);
percentage of time spent practicing medicine, teaching,
or doing administrative tasks; number of years practicing
medicine; geographic location of practice; and physician
age.
For the five SUD-specific questions, physicians were
asked to estimate the number of patients in their active
file (with active file being defined as the total number of
patients seen at least once in the last 12 months) and to
base their responses on these patients. Questions were
designed to collect data about whether physicians were
involved in the management of patients with SUDs; the
number of patients suffering from an SUD for alcohol,
tobacco, cannabis, heroin, stimulants (amphetamines,
cocaine, crack, ecstasy, etc.), hallucinogens (LSD, mush-
rooms, datura, etc.), analgesics (codeine, oxycodone, tram-
adol, etc.), psychoactive drugs (benzodiazepines, etc.),OAT not prescribed by a physician, and non-SUDs
(games, gambling, shopping on credit, sex, Internet); the
number of patients with a heroin use disorder (HUD) who
were also dependent on other substances (alcohol, to-
bacco, ecstasy); the number of patients suffering from
opiate use disorders who were prescribed an OAT (in gen-
eral); and lastly, the number of patients suffering from
opiate use disorders who were prescribed methadone,
buprenorphine (Subutex® or generics), or another OAT
(breakdown per treatment).
Data handling and analysis
To obtain a nationally representative cohort of GPs,
quotas for sex, age, and geographic region were defined
using 2011 medical population data from the international
database of the Cegedim Group (Boulogne-Billancourt
France), which described 60,000 GPs. To obtain a nation-
ally representative cohort of specialists, quotas for gender
and geographic region were also established based on
2011 data from the Cegedim Group. Within these quotas,
GPs and SUD specialists were selected randomly by a
computer-generated program. Physician sample sizes were
determined, taking into account cost of study and reliabil-
ity of responses. For a cohort of 450 GPs, the 95 % confi-
dence interval for a response rate of 30 % was estimated at
25.8–34.2 %.
To maintain physician anonymity during data analysis,
names of physicians were replaced by a computer-
generated random code. Data for GPs and specialists
were analyzed using descriptive statistics. Quantitative
variables were reported as means ± standard deviation,
and qualitative data were reported as n (%). When totals
for demographic data and type of SUD were calculated,
the data from the GPs and specialists were weighted to
match the current distribution of physicians in France.
As this study is primarily a description of GPs, compari-
sons were only performed for general practice and
demographic questions. Comparisons between means
were made using Student’s T-tests. Percentages were
compared by chi-square tests between pairs. Significant
differences were defined at a confidence level of 95 %.
Data were analyzed using software from the Centre for
Open Software Innovation.
Results
The response rate was 44 % for GPs and 68 % for SUD
specialists. Data from 450 GPs and 63 specialists were
included in the analysis.
The cohort of GPs was 71 % male. Mean age was
52 years, and the mean number of years in practice was
22. Fifty-six percent of GPs had been practicing for at
least 21 years (Table 1). The cohort of specialists was
54 % male. Mean age was 52 years, and the mean num-
ber of years in practice was 15. Twenty-two percent of
Table 1 Socio-demographic characteristics: physicians
Total General practitioners SUD specialists
(N = 513) (n = 450) (n = 63)
Gender, % male 71 % 71 % 54 %*
Age
Mean ± SD, years 52 ± 10 52 ± 10 52 ± 9
< 46 years, % 23 % 23 % 23 %
46–50 years, % 13 % 13 % 14 %
51–55 years, % 20 % 20 % 31 %
≥ 56 years, % 44 % 44 % 32 %
Number of years of practice
Mean ± SD, years 21 ± 11.1 22 ± 11 15 ± 10*
0–5 years 12 % 12 % 22 %
6–10 years 10 % 10 % 22 %
11–15 years 7 % 7 % 14 %
16–20 years 15 % 15 % 19 %
21–30 years 33 % 33 % 15 %*
≥ 31 years 22 % 23 % 7 %*
Regional location
Ile-de-Francea 16 % 16 % 22 %
North-East 23 % 23 % 23 %
North-West 22 % 22 % 28 %
South-West 13 % 13 % 10 %
South-East 26 % 26 % 17 %
SD standard deviation, SUD substance use disorder
aParis and surrounding areas
*p < 0.05 vs. the total population
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reported seeing a mean of 3036 patients at least once a
year. When weighted totals were calculated, the mean
age of physicians treating SUDs in France was 52 years,
and the mean number of years in practice was 21. Differ-
ences between the specialist group and the total group
were statistically significant for gender and mean num-
ber of years in practice. Specialists reported seeing a
mean of 920 patients at least once a year.
Patients with SUDs seen by GPs and specialists
Ninety-six percent of GPs (n = 433) reported having at
least one patient with an SUD. The mean number of pa-
tients that these GPs reported seeing at least once a year
was 3061. Tobacco, alcohol, and psychoactive drugs
were the most frequently reported SUDs being managed,
with a mean of 212 (median of 77), 79 (median of 17),
and 63 (median of 14) patients per GP, respectively
(Fig. 1). General practitioners also reported seeing pa-
tients with an analgesic substance use disorder (mean of
17; median of 2 patients per GP), a HUD (mean of 7;
median of 0 patients per GP), and nonprescription OAT
use disorders (mean of 7; median of 0 patients per GP).Ninety-eight percent of specialists (n = 62) reported
having patients with SUDs. The mean number of pa-
tients that these specialists reported seeing at least once
a year was 936. Tobacco, alcohol, heroin, and cannabis
were the most frequently reported SUDs being managed,
with a mean of 310 (median of 144), 292 (median of
198), 145 (median of 28), and 145 (median of 68) pa-
tients per specialist, respectively (Fig. 1). Specialists also
reported seeing patients with analgesic use disorders
(mean of 19; median of 4 patients per specialist) and
nonprescription OAT use disorders (mean of 37; median
of 9 patients per specialist).
Opioid-agonist therapy
Of the 450 physicians surveyed, 35 % of GPs prescribed
an OAT to an average of 4.2 patients (median of 0). Of
these patients, 59 % received a prescription for bupre-
norphine, and 37 % for methadone. In CSAPA centers,
buprenorphine accounted for 37 % of OAT prescrip-
tions, and methadone for 63 %.
Heroin use disorder
Forty-three percent (194/450) of GPs saw at least one
patient with an HUD per year. Thirty-six percent of GPs
reported having between 1 and 10 HUD patients, while
1 % reported having more than 50 HUD patients. Among
GPs who had HUD patients in their practice (n = 194), the
mean number of HUD patients was 14 (median of 3).
General practitioners reported that 83 % of HUD patients
had an SUD for another substance, most often alcohol or
tobacco.
Eighty-two percent (52/63) of specialists saw at
least one HUD patient per year. Among these special-
ists (n = 52), the mean number of HUD patients was
174 (median of 40). Specialists reported that 76 % of
HUD patients had an SUD for another substance.
Eighty-two percent (160/194) of GPs seeing HUD
patients had prescribed OAT during the previous
12 months. This corresponded to an average of 10 pa-
tients per prescriber. Practices, however, were heteroge-
neous: 35 % of physicians treated only 1 or 2 patients,
and 12 % treated 11 patients or more (Fig. 2). Character-
istics of GPs prescribing OAT were not significantly
different (in age, sex, or region) compared to other phy-
sicians in the sample (data not shown).
Discussion
GPs, which are present throughout the course of patient
care, are often the first to witness the emergence of
SUDs and are uniquely positioned to identify associated
SUDs. This study, which was a phone survey of a nation-
ally representative sample of French GPs, confirmed the
fact that GPs have integrated the treatment of SUDs and
non-SUDs into their clinical practice. Ninety-six percent
Fig. 1 Types of substance and non-SUDs in active files of physiciansData were collected about whether physicians were involved in the management
of SUDs and non-SUDs. The active file of a physician was defined as the total group of patients seen at least once in the previous year. Abbreviations:
GPs = general practitioners, benzos = benzodiazepines
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GPs in France are now invested in the care of HUD pa-
tients, as 43 % of GPs reported treating HUDs and 82 %
of these GPs reported prescribing OATs. GPs also re-
ported that 83 % of HUD patients had an associated
SUD. Lastly, GPs also reported having a significant num-
ber of patients with opiate analgesic use disorders, an
area of SUDs that has not been studied extensively in
France.
The first prevalence estimates of problem drug use in
France were made in the mid-1990s. In 1995, the num-
ber of persons with HUDs was estimated to be at leastFig. 2 Percent GPs who prescribed opioid-agonist treatment in the previou160,000, using a demographic method [4]. In 1999, the
number of problem opiate or cocaine users was esti-
mated between 146,000 and 180,000 [4]. In 2006, the es-
timate jumped to 230,000 users [4]. In 2012, the French
Monitoring Center for Drugs and Drug Addiction
(OFDT) estimated the number of problem drug users
(heroin, cocaine, or amphetamines) to be 260,000, of
whom 81,000 were using the intravenous route [5]. Al-
though these data suggest a significant increase in the
number of problem SUDs since 2006 [4], this impression
is misleading [5] as the methods and study populations
have changed. The definition of the group of interest, fors 12 months
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opiate users (1995), to problem opiate or cocaine users
(1999), and finally, to intravenous drug users or regular
users of opiates, cocaine, or amphetamines (2006).
Distribution of GPs in the different regions and the
characteristics of the physicians in our study are similar
to those previously documented in the Cegedim Group
registry. For example, the Cegedim Group reports that
73 % of GPs in France are male; in our sample 71 % of
GPs were male. This comparison suggests that the algo-
rithm that was used to select a nationally representative
cohort of GPs was successful and that our data can be
extrapolated to all of France, with little risk of introdu-
cing significant bias.
When we extrapolated our numbers to all French doc-
tors, we found that there were an estimated 360,000
people suffering from opiate use disorder in France. This
incidence of opiate use disorder is higher than expected.
When a similar extrapolation was made with data from
the “General Practitioners’ Health Barometer 2009”
study, which surveyed 2083 physicians in France and re-
ported similar socio-demographic profiles [6], the num-
ber of people suffering from HUD in France was
estimated to be 110,000. This difference may in part be
due to the fact that our survey did not make the distinc-
tion between experimentation, regular use, and depend-
ence, as defined by the OFDT. In fact, it is likely that the
estimated number of persons with an HUD described by
the GPs in this study (500,000 people according to the
OFDT database) included some experimental users of
heroin [3]. Furthermore, these estimates should be inter-
preted with caution, as there is also the possibility that
patients consulted several doctors. Medical nomadism,
though in decline, has been confirmed by several studies.
In 2007, patients saw on average two GPs per year, and
25 % of patients saw at least three physicians per year
[7]. In the Loire region, 14 % of patients have been
reported to have consulted multiple doctors [8].
Our data support previous data that show that the
changes put in place at the end of the 1990s have
increased the involvement of GPs in the treatment of
SUDs. Since the introduction of high-dose buprenor-
phine (HDB) in private practice, a survey of 1186 GPs
showed that while 53 % of doctors had seen an HUD
patient in the previous year, only 24 % were involved in
ongoing care, and only 13 % of doctors said that when
asked for OAT, they would agree to prescribe buprenor-
phine [9]. In the 2009 “General Practitioners’ Health
Barometer” study, about 50 % of GPs reported seeing at
least one patient with an opiate use disorder per month,
and 87 % of GPs who saw at least one patient with an
opiate use disorder per month prescribed OAT [6]. Simi-
larly, in our study, 43 % of GPs reported seeing at least
one HUD patient per year, and 82 % of these GPs hadprescribed OAT during the previous 12 months. These
data are consistent with data that suggest that more than
60 % of patients with an opiate use disorder are treated
[10] and that 70 % of heroin users received OAT [11].
In addition, our study shows that 59 % of prescriptions
written by GPs for OAT were for buprenorphine and
that 37 % were for methadone. These data suggest a shift
compared to 2007 data, when HDB prescriptions
accounted for 80 % of nonhospital prescriptions for ago-
nisttherapies, and compared to 2010 data, which showed
that HDB accounted for nearly 75 % of all nonhospital
prescriptions [7, 12]. Data from the French national
health insurance service support our findings, as the in-
crease in reimbursement requests rose dramatically be-
tween 2004 and 2010 for methadone (+276 %) compared
to HDB (+29.3 %) [12].
Better physician education about the pathology, treat-
ment strategies, and modalities of OATs [13] are likely
to have contributed to this positive progression in treat-
ment practices. Fears about overdoses associated with
OAT prescriptions [14] appear to be dissipating, possibly
because they are offset by the fact that problems with
aggression tend to decrease with OAT. In addition, the
fact that patients suffering from SUDs consider the rela-
tionship with their physician as an important factor may
also have shifted patients towards seeking help from
their GPs who, by definition, provide a more rounded
approach to patient care [1, 15]. However, the realities of
clinical practice often impose time constraints, which
limit physician availability, and various studies have
shown the necessity of remaining cautious due to the
risk of overdose, especially in combination with benzodi-
azepines [16] and alcohol [17].
Among physicians who do treat patients with an HUD
or an opiate use disorder, the distribution of patients is
uneven [8, 18]. Our data show that GPs can be divided
into two broad groups: one group that sees a few, clearly
identified, and regular patients, and one group that sees
many users. We show that 36 % of GPs treat 10 or fewer
HUD patients, whereas 2 % of GPs treat 30 or more
HUD patients per year. These data are consistent with
previously published data which have shown, for in-
stance, that in the Loire region, a single doctor treated
112 patients with an opiate use disorder using OAT,
whereas 127 doctors in the same region treated only 1
patient per practice [8]. In addition, a 2006 study
showed that 26 % of prescribing doctors in France treat
75 % of all patients [10]. Better distribution of patients
could alleviate some of the time burdens and generally
improve care for SUDs.
This study found few differences in physician practices
across regions (data not shown). These data differ from
those reported by other studies, which have shown het-
erogeneity in OAT prescription practices among GPs
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Sickness Insurance Funds, for example, 35 % of GPs pre-
scribed OAT during the first half of 2002; but in Metz
and Lille, the proportion was larger (50 %) [20]. A more
recent study in the Nord-Pas-de-Calais region showed
that GPs prescribed almost all the OAT for that region
(98.2 % in 2009).
International context
France is not the only country in which GPs have been
heavily implicated in the treatment of SUDs. In the
United Kingdom, GPs play a pivotal role in managing
opiate use disorder [21]. Three times more doctors were
faced with opiate users in 2001 compared to 1985, and
50 % of them prescribed OAT and, more specifically,
methadone. However, questions have been raised about
the quality of care, as the prescribed dose of methadone
(around 30 mg), even if it is relatively safe, is not suffi-
cient for effective “maintenance” [21]. It has been sug-
gested that HDB, which was prescribed by fewer than
5 % of British doctors, could provide a better risk/benefit
ratio [21]. By contrast, in Australia and in Germany, the
focus has been on the obstacles associated with OAT
and as a result, GPs have not been extensively involved
in the treatment of these patients [22–24].
Study limitations
The data in this study must be interpreted in light of the
limitations of its design. Physicians were asked to esti-
mate number of patients over the phone. The level of
subjectivity in this method of data collection is high. In
addition, the questionnaire is not a validated tool and
therefore, the sensitivity and reproducibility of these data
cannot be determined. As previously discussed, the
questionnaire did not differentiate between modalities of
use or degree of dependency, and therefore did not
address notions of recreational use versus SUD. In
addition, our study did not evaluate outcomes of OAT
administered by GPs, and therefore we cannot comment
on whether this shift in practices has led to an improve-
ment in care. Lastly, it is important to note that the
number of SUDs reflect the involvement of physicians.
For example, the number of tobacco use disorders re-
flects number of patients managed by physicians, and
not the number of smokers in France.
Conclusions
Shifts in policy and the development of new treatment
options over the last 20 years have progressively in-
creased the role of French GPs in the treatment of
SUDs, and particularly, in the management of opiate use
disorder. This study provides new data on the practices
of physicians and shows that 96 % of physicians report
treating SUDs. Among physicians who treat HUDpatients, 82 % prescribe OATs. These data suggest that
doctors appear to be convinced of the benefits of OAT
and have overcome their initial concerns [25].
Looking forward, we would like to suggest that GPs
continue to be encouraged to focus on new therapeutic
modalities (drug or nondrug), because prescription OAT,
at an appropriate dosage, optimizes efficacy and reduces
misuse [26, 27]. The value of OAT in new clinical situa-
tions, such as opioid analgesic use disorders, needs to be
explored further [28].
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